US5084482A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Methods for inhibiting inflammatory ischemic, thrombotic and cholesterolemic disease response with methionine compounds
Assignee: Lithox Corp Inc
•
Filing: 1990-04-10
•
Granted: 1992-01-28
•
Expires: 2010-04-10
Abstract
Abstract This invention concerns novel methods employing compositions containing as an active antioxidant or antiinflammatory agent the amino acid methionine, and/or one or more related compounds including certain metabolic precursor compounds, for treating or inhibiting inflammatory ischemic, thrombotic and cholesterolemic disease response in a subject. The compounds include the methionine hydroxy analogs, as well as compounds having the structural formula I: ##STR1## and pharmaceutically acceptable N-(mono- and di-carboxylic acid) acyl derivatives and alkyl esters thereof, where n is an integer from 1 to 3.
Inventors
- 👤 Gerald P. Hirsch
- 👤 Robert K. Bayless
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 14:20
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/21; A61K31/215; A61K31/22; A61K31/185; A61K31/19; A61K31/195
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
86 words
A method for inhibiting inflammatory ischemic, thrombotic and cholesterolemic disease response in a subject in need of such treatment, comprising administration to the subject in oral dosage form an antiinflammatory effective amount of at least one methionine compound selected from the group consisting of the methionine hydroxy analogs, and methionine compounds having the structural formula I ##STR3## and pharmaceutically acceptable N- (mono- and di-carboxylic acid) acyl derivatives of methionine and alkyl esters of methionine compounds and analogs, where n is an integer from 1 to 3.
Claim 2
Independent Claim
86 words
A method for inhibiting inflammatory ischemic, thrombotic and cholesterolemic disease response in a subject in need of such treatment, comprising administration to the subject in oral dosage form an antiinflammatory effective amount of at least one methionine compound selected from the group consisting of the methionine hydroxy analogs, and methionine compounds having the structural formula I ##STR3## and pharmaceutically acceptable N- (mono- and di-carboxylic acid) acyl derivatives of methionine and alkyl esters of methionine compounds and analogs, where n is an integer from 1 to 3.
Claim 3
Dependent Claim
14 words
A method according to claim 1 where the methionine compound is in the dl-form.
Claim 4
Dependent Claim
14 words
A method according to claim 1 where the methionine compound is in the d-form.
Claim 5
Dependent Claim
35 words
A method according to claim 1 where the methionine compound is administered in a daily dosage in the range from 1.0 to 10 grams per 70 kg. of body weight until the inflammation is relieved.
Claim 6
Dependent Claim
87 words
A method according to claim 1 where the dosage form contains in addition at least one homocysteine affecting vitamin selected from the group consisting of vitamin B12, B6, or folic acid, in an amount sufficient to enable the systemic conversion of excess homocysteine present in the system to methionine and cysteine, where the total daily dosage range of vitamin B12, B6 or folic acid corresponds to: vitamin B12, 0.3 to 30 micrograms; vitamin B6, 0.2 to 20 milligrams; folic acid, 40 to 4000 micrograms; and combinations thereof.
Claim 7
Dependent Claim
56 words
A method according to claim 1 where the dosage form contains in addition one homocysteine affecting amino acid selected from the group consisting of serine and glycine, in an amount sufficient to enable the systemic conversion of excess homocysteine present in the system to cysteine, said amount ranging from 1/5 to 3 times the methionine compound.
Claim 8
Dependent Claim
77 words
A method according to claim 1 where the dosage form contains in addition at least one dietary antioxidant in an effective amount selected from a group of dietary antioxidants including vitamins A, C, E, selenium and zinc, where the total daily dosage range for each is: vitamin A, 500 to 50,000 IU; vitamin C, 1 to 1000 mg; vitamin E, 1 to 150 IU; selenium, 1 to 200 mcg; zinc, 1 to 150 mg; and combinations thereof.
Claim 9
Dependent Claim
35 words
A method according to claim 1 where the dosage form contains in addition a coagulation inhibitor in an anticoagulant effective amount, such inhibitor selected from the group including aspirin, dipryidamole, lovastatin, clofibrate, and Dextran 40.
Claim 10
Dependent Claim
48 words
A method according to claim 1 for inhibiting inflammatory response in dogs, cows, pigs or cats where the methionine compound is administered as an N-acyl compound in a daily dosage in the range of 5 to 100 milligrams per kg. of body weight until the inflammation is relieved.
Claim 11
Independent Claim
83 words
A method for inhibiting cholesterolemic disease response in a subject in need of such treatment, comprising provision to the subject a foodstuff comprising essentially the food ingredient and a nutritionally adequate amount of a methionine compound as determined by human nitrogent balance studies or other methods validated thereby, selected from the group consisting of the methionine hydroxy analogs, and l- and dl-methionine compounds; and pharmaceutically acceptable N- (mono- and di-carboxylic acid) acyl derivatives of methionine and alkyl esters of methionine compounds and analogs.
Claim 12
Independent Claim
83 words
A method for inhibiting cholesterolemic disease response in a subject in need of such treatment, comprising provision to the subject a foodstuff comprising essentially the food ingredient and a nutritionally adequate amount of a methionine compound as determined by human nitrogent balance studies or other methods validated thereby, selected from the group consisting of the methionine hydroxy analogs, and l- and dl-methionine compounds; and pharmaceutically acceptable N- (mono- and di-carboxylic acid) acyl derivatives of methionine and alkyl esters of methionine compounds and analogs.
Claim 13
Dependent Claim
52 words
A method according to claim 10, suitable for administration to persons in an institutional setting where the methionine compound is sufficient to provide total l-methionine content in the final food product of more than 3 grams l-methionine per 100 grams protein but less 15 grams of l-methionine compound per 100 grams protein.
Claim 14
Dependent Claim
14 words
A method according to claim 10 where the methionine compound is in the dl-form.
Claim 15
Dependent Claim
14 words
A method according to claim 10 where the methionine compound is in the l-form.
Claim 16
Dependent Claim
86 words
A method according to claim 10 where the dosage form contains in addition at least one homocysteine affecting vitamin selected from the group consisting of vitamin B12, B6, or folic acid, in an amount sufficient to enable the systemic conversion of excess homocysteine present in the system to methionine and cysteine, where the total daily dosage range of vitamin B12, B6 or folic acid corresponds to: vitamin B12, 0.3 to 30 micrograms; vitamin B6, 0.2 to 20 milligrams; folic acid, 40to 4000 micrograms; and combinations thereof.
Claim 17
Dependent Claim
56 words
A method according to claim 10 where the dosage form contains in addition one homocysteine affecting amino acid selected from the group consisting of serine and glycine, in an amount sufficient to enable the systemic conversion of excess homocysteine present in the system to cysteine, said amount ranging from 1/5 to 3 times the methionine compound.
Claim 18
Dependent Claim
77 words
A method according to claim 10 where the dosage form contains in addition at least one dietary antioxidant in a synergistically antioxidant effective amount selected from a group of dietary antioxidants including vitamins A,C,E, selenium, and zinc, where the total daily dosage range for each is: vitamin A, 500 to 50,000 IU; vitamin C, 1 to 1000 mg; vitamin E, 1 to 150 IU; selenium, 1 to 200 mcg; zinc, 1 to 150 mg; and combinations thereof.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-01-27 | 1995-07-29 | 1996-01-28 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-01-27 | 1999-07-29 | 2000-01-28 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-01-27 | 2003-07-29 | 2004-01-28 | $7700.00 | Window Closed / Lapsed |